Immunohistochemical analysis of paraoxonases-1 and 3 in human atheromatous plaques

European Journal of Clinical Investigation

Volumn 41, Issue 3, 2011, Pages 308-314

  Marsillach, Judit ^a   Camps, Jordi ^a   Beltran Debón, Raul ^a   Rull, Anna ^a   Aragones, Gerard ^a   Maestre Martínez, Carmen ^a   Sabench, Fàtima ^b   Hernández, Mercè ^b   Castillo, Daniel D ^b   Joven, Jorge ^a   Mackness, Mike ^a   Mackness, Bharti ^a  

^a INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^b HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

Inflammation; Macrophage; Paraoxonase 1; Paraoxonase 2; Paraoxonase 3

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 3; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROTIC PLAQUE; DISEASE COURSE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MACROPHAGE; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER;

EID: 79551664540     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02411.x     Document Type: Article

References (22)

1. Camps J, Marsillach J, Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci 2009;46:83-106.
2. Lusis AJ. Atherosclerosis. Nature 2000;407:233-41.
3. Aviram M, Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 2004;37:1304-16.
4. Reddy ST, Devarajan A, Bourquard N, Shih D, Fogelman AM. Is it just paraoxonase 1 or are other members of the paraoxonase gene family implicated in atherosclerosis? Curr Opin Lipidol 2008;19:405-8.
5. Mastorikou M, Mackness B, Liu Y, Mackness M. Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolise membrane lipid hydroperoxides. Diabet Med 2008;25:1049-55.
6. Draganov DI, La Du BN. Pharmacogenetics of paraoxonase: a brief review. Naunyn Schmiedebergs Arch Pharmacol 2004;369:78-88.
7. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 2001;276:4444-9.
8. Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A et al. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidised lipids. Arterioscler Thromb Vasc Biol 2001;21:542-7.
9. Marsillach J, Mackness B, Mackness M, Riu F, Beltran R, Joven J et al. Immunohistochemical analysis of paraoxonase-1, 2 and 3 expression in normal mouse tissues. Free Radic Biol Med 2008;45:146-57.
10. Ng CJ, Bourquard N, Hama SY, Shih D, Grijalva VR, Navab M et al. Adenovirus-mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2007;27:1368-74.
11. Mackness B, Hunt R, Durrington PN, Mackness MI. Increased immunolocalisation of paraoxonase, clusterin and apolipoprotein AI in the human artery wall with progression of atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:1233-8.
12. Rosenblat M, Draganov D, Watson CE, Bisgaier CL, La Du BN, Aviram M. Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress. Arterioscler Thromb Vasc Biol 2003;23:468-74.
13. Horke S, Witt I, Wilgenbus P, Kruger M, Strand D, Forstermann U. Paraoxonase-2 reduces oxidative stress in vascular cells and decreases endoplasmic reticulum stress-induced caspase activation. Circulation 2007;115:2055-64.
14. Fortunato G, Di Taranto MD, Bracale UM, Del Guercio L, Carbone F, Mazzacarra C et al. Decreased paraoxonase-2 expression in human carotids during the progression of atherosclerosis. Arterioscler Thromb Vasc Biol 2008;28:594-600.
15. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol 1995;15:1512-31.
16. Shih DM, Gu L, Xia Y-R, Navab M, Li W-F, Hama S et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998;394:284-7.
17. Mackness B, Quarck R, Verreth W, Mackness M, Holvoet P. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler Thromb Vasc Biol 2006;26:1545-50.
18. Draganov DI, Stetson PL, Watson DE, Billecke SS, La Du BN. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 2000;275:33435-42.
19. Teiber JF, Draganov DI, La Du BN. Lactonase and lactonising activities of human serum paraoxonase (PON1) and rabbit serum PON3. Biochem Pharmacol 2003;66:887-96.
20. Liu Y, Mackness B, Mackness M. Comparison of the ability of paraoxonases 1 and 3 to attenuate the in vitro oxidation of low-density lipoprotein and reduce macrophage oxidative stress. Free Radic Biol Med 2008;45:743-8.
21. Shih DM, Xia YR, Wang XP, Bourquard N, Fogelman AM, Lusis AJ et al. Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice. Circ Res 2007;100:1200-7.
22. Zhang C, Peng W, Wang M, Zhu J, Zang Y, Shi W et al. Studies on protective effects of human paraoxonases 1 and 3 on atherosclerosis in apolipoprotein E knock out mice. Gene Ther 2010;17:626-33.